CHARNOCK-JONES David Stephen

This invention relates to the production of rodent endometriosis models by implanting into wild type recipient rodents menstruating endometrium from donor rodents in which an oncogene, such as K-ras, has been activated. Rodent endometriosis…

This invention relates to the production of rodent endometriosis models by implanting into wild type recipient rodents menstruating endometrium from donor rodents in which an oncogene, such as K-ras, has been activated. Rodent endometriosis…

This invention relates to the production of rodent endometriosis models by implanting into wild type recipient rodents menstruating endometrium from donor rodents in which an oncogene, such as K-ras, has been activated. Rodent endometriosis…

This invention relates to the production of rodent endometriosis models by implanting into wild type recipient rodents menstruating endometrium from donor rodents in which an oncogene, such as K-ras, has been activated. Rodent endometriosis…

This invention relates to the production of rodent endometriosis models by implanting into wild type recipient rodents menstruating endometrium from donor rodents in which an oncogene, such as K-ras, has been activated. Rodent endometriosis…

This invention relates to the production of rodent endometriosis models by implanting into wild type recipient rodents menstruating endometrium from donor rodents in which an oncogene, such as K-ras, has been activated. Rodent endometriosis…

This invention relates to the production of rodent endometriosis models by implanting into wild type recipient rodents menstruating endometrium from donor rodents in which an oncogene, such as K-ras, has been activated. Rodent endometriosis…

PCT No. PCT/GB95/01212 Sec. 371 Date May 9, 1997 Sec. 102(e) Date May 9, 1997 PCT Filed May 26, 1995 PCT Pub. No. WO96/32708 PCT Pub. Date Dec. 7, 1995Disclosed are: a composition for use in the treatment of endometriosis, comprising an age…

PCT No. PCT/GB95/01212 Sec. 371 Date May 9, 1997 Sec. 102(e) Date May 9, 1997 PCT Filed May 26, 1995 PCT Pub. No. WO96/32708 PCT Pub. Date Dec. 7, 1995Disclosed are: a composition for use in the treatment of endometriosis, comprising an age…

PCT No. PCT/GB95/01212 Sec. 371 Date May 9, 1997 Sec. 102(e) Date May 9, 1997 PCT Filed May 26, 1995 PCT Pub. No. WO96/32708 PCT Pub. Date Dec. 7, 1995Disclosed are: a composition for use in the treatment of endometriosis, comprising an age…

PCT No. PCT/GB95/01212 Sec. 371 Date May 9, 1997 Sec. 102(e) Date May 9, 1997 PCT Filed May 26, 1995 PCT Pub. No. WO96/32708 PCT Pub. Date Dec. 7, 1995Disclosed are: a composition for use in the treatment of endometriosis, comprising an age…

PCT No. PCT/GB95/01212 Sec. 371 Date May 9, 1997 Sec. 102(e) Date May 9, 1997 PCT Filed May 26, 1995 PCT Pub. No. WO96/32708 PCT Pub. Date Dec. 7, 1995Disclosed are: a composition for use in the treatment of endometriosis, comprising an age…

PCT No. PCT/GB95/01212 Sec. 371 Date May 9, 1997 Sec. 102(e) Date May 9, 1997 PCT Filed May 26, 1995 PCT Pub. No. WO96/32708 PCT Pub. Date Dec. 7, 1995Disclosed are: a composition for use in the treatment of endometriosis, comprising an age…

PCT No. PCT/GB95/01212 Sec. 371 Date May 9, 1997 Sec. 102(e) Date May 9, 1997 PCT Filed May 26, 1995 PCT Pub. No. WO96/32708 PCT Pub. Date Dec. 7, 1995Disclosed are: a composition for use in the treatment of endometriosis, comprising an age…

Disclosed are: a composition for use in the treatment of endometriosis, comprising an agent capable of interfering with the production and/or activity of VEGF, and a physiologically acceptable carrier substance; a composition for the treatm…

Disclosed are: a composition for use in the treatment of endometriosis, comprising an agent capable of interfering with the production and/or activity of VEGF, and a physiologically acceptable carrier substance; a composition for the treatm…

Disclosed are: a composition for use in the treatment of endometriosis, comprising an agent capable of interfering with the production and/or activity of VEGF, and a physiologically acceptable carrier substance; a composition for the treatm…

Disclosed are: a composition for use in the treatment of endometriosis, comprising an agent capable of interfering with the production and/or activity of VEGF, and a physiologically acceptable carrier substance; a composition for the treatm…

Disclosed are: a composition for use in the treatment of endometriosis, comprising an agent capable of interfering with the production and/or activity of VEGF, and a physiologically acceptable carrier substance; a composition for the treatm…

Disclosed are: a composition for use in the treatment of endometriosis, comprising an agent capable of interfering with the production and/or activity of VEGF, and a physiologically acceptable carrier substance; a composition for the treatm…

Disclosed are: a composition for use in the treatment of endometriosis, comprising an agent capable of interfering with the production and/or activity of VEGF, and a physiologically acceptable carrier substance; a composition for the treatm…

Disclosed are: a composition for use in the treatment of endometriosis, comprising an agent capable of interfering with the production and/or activity of VEGF, and a physiologically acceptable carrier substance; a composition for the treatm…

Disclosed are: a composition for use in the treatment of endometriosis, comprising an agent capable of interfering with the production and/or activity of VEGF, and a physiologically acceptable carrier substance; a composition for the treatm…

Disclosed are: a composition for use in the treatment of endometriosis, comprising an agent capable of interfering with the production and/or activity of VEGF, and a physiologically acceptable carrier substance; a composition for the treatm…

Disclosed are: a composition for use in the treatment of endometriosis, comprising an agent capable of interfering with the production and/or activity of VEGF, and a physiologically acceptable carrier substance; a composition for the treatm…